Armistice Capital LLC Boosts Stock Holdings in Autolus Therapeutics PLC Sponsored ADR $AUTL

Armistice Capital LLC lifted its position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500,000 shares of the company’s stock after acquiring an additional 1,900,000 shares during the period. Armistice Capital LLC owned approximately 6.58% of Autolus Therapeutics worth $34,825,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in AUTL. Independent Advisor Alliance purchased a new stake in Autolus Therapeutics during the 4th quarter valued at $28,000. Marex Group plc purchased a new position in shares of Autolus Therapeutics in the second quarter worth $28,000. SmartHarvest Portfolios LLC bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at $43,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Autolus Therapeutics during the third quarter valued at $46,000. Finally, R Squared Ltd boosted its position in shares of Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after buying an additional 8,730 shares during the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Trading Up 2.7%

Shares of NASDAQ AUTL opened at $1.53 on Thursday. Autolus Therapeutics PLC Sponsored ADR has a 12-month low of $1.18 and a 12-month high of $2.70. The firm has a market capitalization of $407.22 million, a price-to-earnings ratio of -1.40 and a beta of 2.02. The firm has a 50 day moving average of $1.58 and a 200 day moving average of $1.56.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The business had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. Sell-side analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.96 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on AUTL shares. Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Mizuho cut their target price on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, March 31st. Finally, Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.75.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.